公开(公告)号：US20190119713A1

公开(公告)日：2019-04-25

申请号：US16018400

申请日：2018-06-26

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Chung-Yi WU ,  Che MA

IPC: C12P19/14 ,  C07K16/28 ,  A61K45/06 ,  C07K16/32 ,  A61K39/395 ,  C12N9/24 ,  C07K16/10 ,  C07K16/00 ,  A61K39/42 ,  C07K16/30 ,  C07K16/18 ,  C07K16/24

Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

公开(公告)号：US20240299567A1

公开(公告)日：2024-09-12

申请号：US18272107

申请日：2022-01-14

Applicant: Ming-Che SHIH ,  Academia Sinica

Inventor： Che MA ,  Wen-Hwa LEE ,  Tracer YONG

IPC: A61K47/64 ,  A61K39/00 ,  A61P35/04 ,  C07K14/715

CPC classification number: A61K47/646 ,  A61K47/6415 ,  A61P35/04 ,  C07K14/7155 ,  A61K39/00 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/645 ,  C07K2319/40

Abstract: Disclosed herein is a recombinant polypeptide comprising 1 to 20 copies of an IL-17RB inactivation site (IRIS) sequence. Also disclosed herein is the use of the recombinant polypeptide in the preparation of a conjugate for the treatment of cancers.

公开(公告)号：US20240016917A1

公开(公告)日：2024-01-18

申请号：US18005573

申请日：2022-04-12

Applicant: ACADEMIA SINICA

Inventor： Che MA ,  Chi-Huey WONG ,  Han-Yi HUANG

IPC: A61K39/215 ,  A61P31/04

CPC classification number: A61K39/215 ,  A61P31/04 ,  A61K2039/55505

Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

公开(公告)号：US20230302114A1

公开(公告)日：2023-09-28

申请号：US17998208

申请日：2021-05-07

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey WONG ,  Hsin-Yu LIAO ,  Shih-Chi WANG ,  Yi-An KO ,  Kuo-I LIN ,  Che MA ,  Ting-Jen CHENG

IPC: A61K39/145 ,  C07K14/005 ,  A61P31/16

CPC classification number: A61K39/145 ,  A61P31/16 ,  C07K14/005 ,  A61K2039/575

Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

公开(公告)号：US20210386820A1

公开(公告)日：2021-12-16

申请号：US17274122

申请日：2019-09-06

Applicant: ACADEMIA SINICA

Inventor： Che MA ,  Yu-Min LIU ,  Jia-Tsrong JAN

IPC: A61K38/17 ,  A61P31/16

Abstract: The present invention relates to antiviral lectin and uses thereof. Particularly, the present invention relates to a complex-type (CX-type) and/or hybrid-type (HY-type) glycan binding lectin for use in treating or preventing influenza virus infection. The present invention also provides a method for treating or preventing influenza virus infection by administrating to a subject in need said lectin or a composition comprising the same.